Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine

Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome

(2019) Supriya Ravichandran et al.   Nature Communications

Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans

(2019) Surender Khurana et al.   Nature Communications

Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions withPlasmodium falciparumCircumsporozoite Protein Antigens

(2018) S. Moses Dennison et al.   JOURNAL OF IMMUNOLOGY

Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope

(2018) Stefan W. Metz et al.   Virology Journal

The immune response against flaviviruses

(2018) Jose Luis Slon Campos et al.   NATURE IMMUNOLOGY

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study

(2017) Xavier Sáez-Llorens et al.   LANCET INFECTIOUS DISEASES

The development of therapeutic antibodies against dengue virus

(2016) Guntur Fibriansah et al.   ANTIVIRAL RESEARCH

How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses

(2016) P. J. Klasse   Expert Review of Vaccines

An elaborate landscape of the human antibody repertoire against enterovirus 71 infection is revealed by phage display screening and deep sequencing

(2016) Zhe Chen et al.   mAbs

Initiation of immune tolerance–controlled HIV gp41 neutralizing B cell lineages

(2016) Ruijun Zhang et al.   Science Translational Medicine

Evaluation of potential immunogenicity differences betweenPandemrix™ andArepanrix™

(2016) Quentin Canelle et al.   Human Vaccines & Immunotherapeutics

Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs

(2016) Josefine Persson et al.   Frontiers in Immunology

Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity

(2015) Louis Lau et al.   JOURNAL OF CLINICAL VIROLOGY

Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study

(2015) Chukiat Sirivichayakul et al.   JOURNAL OF INFECTIOUS DISEASES

A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins

(2015) Guntur Fibriansah et al.   Nature Communications

Strategies to guide the antibody affinity maturation process

(2015) Nicole A Doria-Rose et al.   Current Opinion in Virology

Single-Cell and Deep Sequencing of IgG-Switched Macaque B Cells Reveal a Diverse Ig Repertoire following Immunization

(2014) C. Sundling et al.   JOURNAL OF IMMUNOLOGY

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

(2014) Jorge E Osorio et al.   LANCET INFECTIOUS DISEASES

Rapid development of broadly influenza neutralizing antibodies through redundant mutations

(2014) Leontios Pappas et al.   NATURE

Antibody avidity measurements in recipients of Cervarix® vaccine following a two-dose schedule or a three-dose schedule

(2014) Mathieu Boxus et al.   VACCINE

Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen

(2013) Heather E. Lynch et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Functional Analysis of Antibodies against Dengue Virus Type 4 Reveals Strain-Dependent Epitope Exposure That Impacts Neutralization and Protection

(2013) S. Sukupolvi-Petty et al.   JOURNAL OF VIROLOGY

High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection

(2013) Wen-Yang Tsai et al.   JOURNAL OF VIROLOGY

The global distribution and burden of dengue

(2013) Samir Bhatt et al.   NATURE

The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein

(2013) S. A. Smith et al.   mBio

Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in Humans

(2013) Andreas Puschnik et al.   PLoS Neglected Tropical Diseases

Germinal Centers

(2012) Gabriel D. Victora et al.   Annual Review of Immunology

Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic

(2012) Mark Dysinger et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

(2012) R. de Alwis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody

(2012) E. P. Teoh et al.   Science Translational Medicine

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

(2010) Bimmi Shrestha et al.   PLoS Pathogens

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

(2008) Jens Wrammert et al.   NATURE